Research News

This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19. The virus shown was isolated from a patient in the U.S.NIAID-RML

Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19, according to National Institutes of Health scientists.

An investigational vaccine called ChAdOx1 MERS protected two groups of rhesus macaques from disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV).  MERS-CoV is a relative of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19).  National Institutes of Health scientists and colleagues are pursuing similar studies with ChAdOx1 SARS2, a vaccine candidate against SARS-CoV-2. They posted their results(link is external) with ChAdOx1 MERS on a preprint server. The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.

The swell of novel coronavirus appears not abating. In just a few months from the outbreak, it has reached around 210 countries, took lives of more than one lakh people. The numbers are climbing. In an effort to place a hurdle before the runaway train, scientists across the globe are racing to develop a drug that can cure or a vaccine that stop its spread.

Researchers at Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram are in the final stages of developing a kit that promises to help detect SARS CoVID-19 infection as early as four days post-infection of the virus.

Indian scientists are working day and night to find solutions against the threat of Covid-19. Scientists from Central Salt and Marine Chemical Research Institute (CSMCRI), located in Bhavnagar, Gujarat, have developed a unique face-mask, which can destroy the virus.

Loss of smell and taste has been anecdotally linked to COVID-19 infections. In a study published April 12, 2020 in the journal International Forum of Allergy & Rhinology , researchers at UC San Diego Health report the first empirical findings that strongly associate sensory loss with COVID-19, the respiratory disease caused by the novel coronavirus.

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), University of California San Diego researchers moved one step closer to the ability to make heparin in cultured cells. Heparin is a potent anti-coagulant and the most prescribed drug in hospitals, yet cell-culture-based production of heparin is currently not possible.

Our research institutions are increasingly translating their knowledge into challenging and useful applications. This product from JNCASR is a compelling example of that”- Prof Ashutosh Sharma, Secretary, DST